Scintomics and 1717 Life Science Ventures Team up in the Joint Venture PENTIXAPHARM to Develop CXCR4-Targeted Theranostics
15.5.2019 19:53:00 EEST | Business Wire | Press release
Scintomics GmbH and 1717 Life Science Ventures GmbH announced today to have signed an agreement to collaborate in the development of the theranostic pair PentixaFor / PentixaTher.
PentixaPharm GmbH, based in Würzburg, is committed to develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers.
Interviews: “We are delighted that in 1717 LSV we have found a strong partner with an outstanding expertise in the clinical development of precision oncologics. Taking the various recent and successful proof-of-concept studies with PentixaFor and PentixaTher in men into account, this joint venture creates optimal conditions for the effective and swift clinical development of this unrivalled and unique pair of theranostic drugs”, said Prof. Hans-Jürgen Wester, PhD, Founder of Scintomics and Chair for Pharmaceutical Radiochemistry at the Technical University of Munich (TUM), Germany.
“The introduction of 68 Ga-PentixaFor may be regarded as a milestone for clinical PET imaging of CXCR4 expressing malignancies”, added Dr. Hakim Bouterfa Co-founder of 1717 LSV GmbH and CEO of PentixaPharm. “Now we will focus on the next major step to provide CXCR4-directed endoradiotherapy in prospective clinical trials.”
About PentixaFor / PentixaTher
This theranostic pair specifically targets the CXCR4-CXCR12 axis, which is significantly involved in the interaction and proliferation of hematologic and solid tumors and their protective environment. The Gallium-68 based PET agent PentixaFor has demonstrated advanced imaging not only for several different hematologic indications – including leukaemia, lymphoma, and multiple myeloma – but also for other solid tumors like adrenocortical carcinoma, and small cell lung cancer. In addition, other disease conditions, such as atherosclerosis, myocardial infarction, splenosis and stroke and can be targeted with this tracer. The therapeutic counterpart PentixaTher, labeled with α- or β-emitters, offers new treatment options for individualised medicine in terms of endoradiotherapy.
About Scintomics GmbH
Scintomics, based in Fuerstenfeldbruck/Munich, is a privately held company for innovative-targeted theranostics and corresponding radiopharmaceutical technologies with a strong commitment towards personalized cancer care with an exceptional pipeline of functional diagnostics and radiotherapeutics. Scintomics considers the joint venture partnership with 1717 LSV as another important milestone towards a strong positioning as radiopharmaceutical development specialist.
About 1717 LSV GmbH
1717 LSV, based in Berlin, is a privately held company with expertise in the development of targeted precision radiopharmaceuticals for the targeted diagnosis and treatment of malignant oncological diseases. By enabling novel radiopharmaceutical therapies to traverse early stages of manufacturing and clinical development, 1717 LSV brings innovative drug candidates to patients with unmet medical needs.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005776/en/
Contact information
For Scintomics
Saskia Kropf
General Manager
tel.
+49 8141 150 550
s.kropf@scintomics.com
www.scintomics.com
For
1717 LSV
Dr. Jens Kaufmann
General Manager
tel. +49
30 941084-422
jens.kaufmann@1717LSV.com
www.1717LSV.com
For
PentixaPharm
Dr. Hakim Bouterfa
CEO
tel. +49 172
6290822 or +49 931 304998310
hakim.bouterfa@1717LSV.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sofinnova Partners Promotes Javier Nunez-Vicandi to Partner, Strengthening Its Digital Medicine Strategy2.11.2026 09:00:00 EET | Press release
Sofinnova Partners ("Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, today announced the promotion of Javier Nunez-Vicandi to Partner. He joins Edward Kliphuis and Simon Turner in the firm’s Digital Medicine strategy, which invests in startups working at the intersection of biology, data, and AI. Since joining Sofinnova in 2022, Nunez-Vicandi has played a key role in the development of the firm's Digital Medicine strategy and broader AI efforts. He helped shape key AI investment theses within the Digital Medicine Strategy and is an observer on the boards of Latent Labs, Bioptimus, Cure51, Deepc, and Kiro. Javier has also recently led an investment that remains in stealth. Within Sofinnova's broader AI efforts, Javier co-led the project that created Sofia, Sofinnova's proprietary AI platform, which supports investments and scientific analysis. As part of this effort, Javier helped lead the firm's collaborations with AWS and NVIDI
SES to Supply Finnair with Ground-like Connectivity Experience in the Skies2.11.2026 09:00:00 EET | Press release
SES today announced a new agreement with Finnair, Finland's flagship airline, to equip 18 E195-E2s with multi-orbit in-flight connectivity, enabling Finnair’s customers to enjoy fast, reliable internet access throughout their journey. Under the agreement, the Embraer E2 aircraft, which will be line-fitted at Embraer, will be equipped with SES’s electronically steered array antenna (ESA) offering reliable connectivity to the SES multi-orbit network, combining SES’s geostationary (GEO) satellite services with low-earth orbit (LEO) capacity from its partner Eutelsat. The first connected aircraft is expected to enter service in 2027. “Inflight Wi-Fi is a core part of the travel experience,” said Blane Boynton, Senior Vice President Aviation at SES. “SES’s multi-orbit network delivers the reliability, performance and flexibility airlines need today while providing a clear path for future growth. This agreement is another testament to the growing confidence leading airlines are placing in ou
Speech Processing Solutions Launches Philips SpeechLive Legal Direct and Philips SpeechLive Professional Direct with Real-Time Speech Recognition Directly at Cursor2.11.2026 09:00:00 EET | Press release
Speech Processing Solutions (SPS), the global leader in professional dictation and transcription solutions sold under the Philips brand, today announced the launch of Philips SpeechLive Legal Direct and Philips SpeechLive Professional Direct. The two solutions allow legal and other professionals to dictate into supported desktop applications, with recognized text appearing as they speak. They are designed both for organizations adopting professional speech recognition for the first time and for customers moving from established or end-of-life speech recognition solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029365830/en/ Philips SpeechLive Legal Direct – legal speech recognition, directly at cursor With support of 29 voice commands across 19 languages, these new solutions combine familiar dictation practices with commands covering navigation, selection, editing, formatting, lists and help functions. Professiona
Thales Selected to Deliver Next-Generation Mine-Hunting Capability for the U.S. Navy2.11.2026 08:00:00 EET | Press release
Thales’ subsidiary Advanced Acoustic Concepts (AAC), a U.S.-based provider of undersea warfare solutions, was awarded a $53.9 million U.S. Navy contract to produce and deliver two integrated Remote Mine Hunting (RMH) modules and accompanying engineering support. The award includes options for additional modules that could increase the total cumulative contract value to approximately $196.2 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261101304707/en/ Sonar ©Thales The RMH solution supports the Navy's Mine Countermeasures (MCM) mission through the proven “Find, Fix and Finish” approach to defeating mine threats. The capability enables sailors to remotely detect, locate and classify undersea mines, while operating from safer stand-off distances, enhancing mission effectiveness and reducing risk in contested maritime environments. “The ability to counter undersea mine threats remains fundamental to maritime security
Uptime Institute and Indonesia Ministry of Communication and Digital Affairs (KOMDIGI) Sign Letter of Intent (LOI) to Support Data Center Policy, Governance, and Industry Development2.11.2026 07:04:00 EET | Press release
Uptime Institute, the Global Digital Infrastructure Authority, and the Ministry of Communication and Digital Affairs (Komdigi) today announced the signing of a Letter of Intent (LOI) to explore collaboration aimed at strengthening Indonesia's data center ecosystem through policy development, governance frameworks, operational excellence, security, sustainability, and workforce capability development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261101628182/en/ Uptime Institute and KOMDIGI sign LOI. The Letter of Intent reflects a shared interest in exploring international best practices that may support the development of reliable, secure, efficient, and sustainable digital infrastructure aligned with Indonesia's national priorities and regulatory framework. The LOI was signed by Mustapha Louni, Chief Business Officer, Uptime Institute, and Wayan Toni Supriyanto, Director General of Digital Infrastructure, Indonesia's Min
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom